close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bright Peak Therapeutics, Inc.

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Tickers ANAB DSGN XERS
Bright Peak Therapeutics to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional PD1-IL18 Immunocytokine
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today